Mentions
Extended reach
Total likes
Video views
AI synopsis
The discussions emphasize the high response rates (e.g., 73% objective response, 53% complete response), and words like 'high', 'approved', and 'study' reflect a tone of achievement and significance. Participants incorporate professional insights, personal experiences, and references to approval processes, illustrating both interest and perceived impact of the therapy on lymphoma treatments.
Most discussions recognize the positive outcomes and approval of LISocabtagene maraleucel, indicating general agreement with its clinical significance.
Participants show high interest, highlighting the therapy's promising efficacy and real-world application across different settings.
Users engage actively by sharing study results, personal connections, and professional insights, suggesting moderate but meaningful involvement.
The widespread mention and approval by authorities like the FDA suggest the therapy has a noteworthy impact on treatment options and future research.
In this multicenter study we participated in, lisocabtagene maraleucel in R/R large B-cell lymphoma pts resulted in a high objective response rate and is currently used as a CAR T cell therapy for relapsed #mantlecelllymphoma in an ongoing clinical trial. https://t.co/Us6fHi1RFw
The study by Jeremy Abramson et al showed Lisocabtagene maraleucel, an autologous, CD19-directed, CAR T-cell product for pts with R/R large B-cell lymphomas (TRANSCEND NHL 001). Of 256 pts included in efficacy-evaluable set, OR seen in 73% pts & CR in 53% https://t.co/Us6fHi1RFw
I was honored to have her on my show @Plenary_Session not just once https://t.co/qdsWibuKXc
.@US_FDA Approves Lisocabtagene Maraleucel for Patients With Relapsed or Refractory Large B-Cell Lymphoma https://t.co/2G4UHL89Ip @FDAOncology #lymsm #hematology
4/ Dr. An discussed the results of the TRANSCEND NHL 001 study evaluating the autologous CD19-directed CAR T-cell agent liso-cel that resulted in ⬆️ response rates in pts w/ R/R large B-cell lymphomas
Our CAR T research lead to authorship (Nilanjan Ghosh, MD, PhD) on the TRASNCEND CAR T study published in Lancet (2020): https://t.co/GuBaHb0r0M #CARTCellLCI #lymsm #mmsm
This Harvard Medical School video explains what CAR T cells are, their use in lymphoma, and associated toxicities, including cytokine release syndrome, ICANS, and cytopenias, with insights into therapy logistics and…
We discuss public health messaging during the COVID-19 pandemic, focusing on the Northeast U.S. region's unique response strategies, with insights from experts at Harvard and Dartmouth, along with recent developments in…
RT @michaelwangmd: The study by Jeremy Abramson et al showed Lisocabtagene maraleucel, an autologous, CD19-directed, CAR T-cell product for…
RT @michaelwangmd: The study by Jeremy Abramson et al showed Lisocabtagene maraleucel, an autologous, CD19-directed, CAR T-cell product for…
RT @michaelwangmd: The study by Jeremy Abramson et al showed Lisocabtagene maraleucel, an autologous, CD19-directed, CAR T-cell product for…
The study by Jeremy Abramson et al showed Lisocabtagene maraleucel, an autologous, CD19-directed, CAR T-cell product for pts with R/R large B-cell lymphomas (TRANSCEND NHL 001). Of 256 pts included in efficacy-evaluable set, OR seen in 73% pts & CR in 53% https://t.co/Us6fHi1RFw
RT @michaelwangmd: In this multicenter study we participated in, lisocabtagene maraleucel in R/R large B-cell lymphoma pts resulted in a hi…
RT @michaelwangmd: In this multicenter study we participated in, lisocabtagene maraleucel in R/R large B-cell lymphoma pts resulted in a hi…
In this multicenter study we participated in, lisocabtagene maraleucel in R/R large B-cell lymphoma pts resulted in a high objective response rate and is currently used as a CAR T cell therapy for relapsed #mantlecelllymphoma in an ongoing clinical trial. https://t.co/Us6fHi1RFw
I was honored to have her on my show @Plenary_Session not just once https://t.co/qdsWibuKXc
RT @ASCOPost: .@US_FDA Approves Lisocabtagene Maraleucel for Patients With Relapsed or Refractory Large B-Cell Lymphoma https://t.co/2G4UHL…
RT @ASCOPost: .@US_FDA Approves Lisocabtagene Maraleucel for Patients With Relapsed or Refractory Large B-Cell Lymphoma https://t.co/2G4UHL…
.@US_FDA Approves Lisocabtagene Maraleucel for Patients With Relapsed or Refractory Large B-Cell Lymphoma https://t.co/2G4UHL89Ip @FDAOncology #lymsm #hematology
FDA Approves Lisocabtagene Maraleucel for Patients With Relapsed or Refractory Large B-Cell Lymphoma - The ASCO Post https://t.co/7Q0ya6acjw
4/ Dr. An discussed the results of the TRANSCEND NHL 001 study evaluating the autologous CD19-directed CAR T-cell agent liso-cel that resulted in ⬆️ response rates in pts w/ R/R large B-cell lymphomas
Our CAR T research lead to authorship (Nilanjan Ghosh, MD, PhD) on the TRASNCEND CAR T study published in Lancet (2020): https://t.co/GuBaHb0r0M #CARTCellLCI #lymsm #mmsm
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. #lymphoma #lymsm https://t.co/18UN2hG9hS
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas… https://t.co/7Wwec7IFh1
New article: Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. https://t.co/SRVft1tQU8 #FL #lymsm #hematology https://t.co/pSLnIC7IHp